Your browser doesn't support javascript.
loading
Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021.
Kim, Sara S; Chung, Jessie R; Belongia, Edward A; McLean, Huong Q; King, Jennifer P; Nowalk, Mary Patricia; Zimmerman, Richard K; Balasubramani, Goundappa K; Martin, Emily T; Monto, Arnold S; Lamerato, Lois E; Gaglani, Manjusha; Smith, Michael E; Dunnigan, Kayan M; Jackson, Michael L; Jackson, Lisa A; Tenforde, Mark W; Verani, Jennifer R; Kobayashi, Miwako; Schrag, Stephanie J; Patel, Manish M; Flannery, Brendan.
Affiliation
  • Kim SS; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Chung JR; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Belongia EA; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • McLean HQ; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • King JP; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
  • Nowalk MP; University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania, USA.
  • Zimmerman RK; University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania, USA.
  • Balasubramani GK; University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania, USA.
  • Martin ET; University of Michigan, Ann Arbor, Michigan, USA.
  • Monto AS; University of Michigan, Ann Arbor, Michigan, USA.
  • Lamerato LE; Henry Ford Health System, Detroit, Michigan, USA.
  • Gaglani M; Baylor Scott and White Health.
  • Smith ME; Texas A&M University College of Medicine, Temple, Texas, USA.
  • Dunnigan KM; Baylor Scott and White Health.
  • Jackson ML; Baylor Scott and White Health.
  • Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
  • Tenforde MW; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
  • Verani JR; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kobayashi M; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Schrag SJ; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Patel MM; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Flannery B; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J Infect Dis ; 224(10): 1694-1698, 2021 11 22.
Article in En | MEDLINE | ID: mdl-34498052
Evaluations of vaccine effectiveness (VE) are important to monitor as coronavirus disease 2019 (COVID-19) vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged ≥16 years, the VE of messenger RNA vaccines against COVID-19 was 91% (95% confidence interval, 83%-95%) for full vaccination and 75% (55%-87%) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Diagnostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Infect Dis Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Type of study: Diagnostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Infect Dis Year: 2021 Document type: Article Affiliation country: Country of publication: